{"id":7749,"date":"2026-04-28T16:47:46","date_gmt":"2026-04-28T13:47:46","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=7749"},"modified":"2026-04-28T16:47:47","modified_gmt":"2026-04-28T13:47:47","slug":"sgt-003-eu-orphan-drug-duchenne","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/pt\/sgt-003-eu-orphan-drug-duchenne\/","title":{"rendered":"A Comiss\u00e3o Europeia concede a designa\u00e7\u00e3o de medicamento \u00f3rf\u00e3o ao SGT-003 para a distrofia muscular de Duchenne."},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>A Comiss\u00e3o Europeia concedeu a designa\u00e7\u00e3o de medicamento \u00f3rf\u00e3o ao SGT-003, uma terapia gen\u00e9tica promissora desenvolvida pela Solid Biosciences, para o tratamento da distrofia muscular de Duchenne (DMD).<\/strong>. Este marco destaca o crescente apoio regulat\u00f3rio a terapias inovadoras direcionadas a doen\u00e7as raras com grandes necessidades m\u00e9dicas n\u00e3o atendidas.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u00cdndice<\/h2><nav><ul><li><a href=\"#what-is-sgt-003\">O que \u00e9 SGT-003?<\/a><\/li><li><a href=\"#regulatory-milestone-orphan-drug-designation\">Marco regulat\u00f3rio: Designa\u00e7\u00e3o de medicamento \u00f3rf\u00e3o<\/a><\/li><li><a href=\"#global-regulatory-momentum\">Impulso regulat\u00f3rio global<\/a><\/li><li><a href=\"#ongoing-clinical-trials\">Ensaios cl\u00ednicos em andamento<\/a><\/li><li><a href=\"#why-this-matters-for-duchenne-patients\">Por que isso \u00e9 importante para pacientes com distrofia muscular de Duchenne?<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-sgt-003\"><strong>O que \u00e9 SGT-003?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">SGT-003 \u00e9 uma terapia g\u00eanica experimental desenvolvida para tratar a causa gen\u00e9tica subjacente da distrofia muscular de Duchenne (DMD). A terapia visa fornecer uma vers\u00e3o funcional do gene da distrofina, potencialmente melhorando a fun\u00e7\u00e3o muscular e retardando a progress\u00e3o da doen\u00e7a. Saiba mais: <a href=\"https:\/\/dmdwarrior.com\/pt\/faq-solid-biosciences-sgt-003-gene-therapy\/\" target=\"_blank\" rel=\"noreferrer noopener\">Perguntas frequentes sobre a terapia g\u00eanica SGT-003<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"regulatory-milestone-orphan-drug-designation\"><strong>Marco regulat\u00f3rio: Designa\u00e7\u00e3o de medicamento \u00f3rf\u00e3o<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">A designa\u00e7\u00e3o de medicamento \u00f3rf\u00e3o concedida pela Comiss\u00e3o Europeia surge na sequ\u00eancia de um parecer favor\u00e1vel do Comit\u00e9 de Medicamentos \u00d3rf\u00e3os da Ag\u00eancia Europeia de Medicamentos.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Essa designa\u00e7\u00e3o oferece diversas vantagens importantes:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Exclusividade de mercado na UE<\/li>\n\n\n\n<li>Taxas regulat\u00f3rias reduzidas<\/li>\n\n\n\n<li>Acesso \u00e0 assist\u00eancia de protocolo<\/li>\n\n\n\n<li>Suporte aprimorado para o desenvolvimento<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Segundo Jessie Hanrahan, esse reconhecimento refor\u00e7a o potencial do SGT-003 para atender \u00e0s necessidades cr\u00edticas ainda n\u00e3o atendidas de pacientes com distrofia muscular de Duchenne em todo o mundo.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"global-regulatory-momentum\"><strong>Impulso regulat\u00f3rio global<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">O SGT-003 recebeu diversas designa\u00e7\u00f5es regulat\u00f3rias nos principais mercados, demonstrando forte alinhamento internacional:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Da Administra\u00e7\u00e3o de Alimentos e Medicamentos dos EUA:\n<ul class=\"wp-block-list\">\n<li>Designa\u00e7\u00e3o Fast Track<\/li>\n\n\n\n<li>Designa\u00e7\u00e3o de medicamento \u00f3rf\u00e3o<\/li>\n\n\n\n<li>Designa\u00e7\u00e3o de Doen\u00e7a Pedi\u00e1trica Rara<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li>Do quadro regulamentar do Reino Unido:\n<ul class=\"wp-block-list\">\n<li>Passaporte de Inova\u00e7\u00e3o no \u00e2mbito da Licen\u00e7a de Inova\u00e7\u00e3o e do Programa de Acesso<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Essas designa\u00e7\u00f5es aceleram os cronogramas de desenvolvimento e facilitam uma colabora\u00e7\u00e3o mais estreita com os \u00f3rg\u00e3os reguladores.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"ongoing-clinical-trials\"><strong>Ensaios cl\u00ednicos em andamento<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">O SGT-003 est\u00e1 atualmente sendo avaliado em dois grandes estudos cl\u00ednicos:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong><a href=\"https:\/\/dmdwarrior.com\/pt\/solid-biosciences-provides-update-on-inspire-duchenne-clinical-trial-progress-and-planned-regulatory-discussions\/\">INSPIRE DUCHENNE<\/a><\/strong><br>Ensaio cl\u00ednico de fase 1\/2 para avalia\u00e7\u00e3o da seguran\u00e7a e efic\u00e1cia inicial.<\/li>\n\n\n\n<li><strong><a href=\"https:\/\/dmdwarrior.com\/pt\/solid-biosciences-sgt-003-gene-therapy-phase-3-clinical-trial-nct07160634\/\">IMPACT DUCHENNE<\/a><\/strong><br>Ensaio cl\u00ednico de fase 3, randomizado, duplo-cego e controlado por placebo.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Esses ensaios cl\u00ednicos s\u00e3o projetados para dar suporte \u00e0s aprova\u00e7\u00f5es regulat\u00f3rias em diversas regi\u00f5es.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"why-this-matters-for-duchenne-patients\"><strong>Por que isso \u00e9 importante para pacientes com distrofia muscular de Duchenne?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">A distrofia muscular de Duchenne \u00e9 uma doen\u00e7a gen\u00e9tica grave e progressiva com op\u00e7\u00f5es de tratamento limitadas. O avan\u00e7o de terapias gen\u00e9ticas como a SGT-003 representa uma potencial mudan\u00e7a de paradigma, passando do controle dos sintomas para interven\u00e7\u00f5es que modificam a doen\u00e7a.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Siga esta p\u00e1gina<\/strong>&nbsp;&gt;&gt;&gt;&nbsp;<a href=\"https:\/\/dmdwarrior.com\/pt\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Todos os ensaios cl\u00ednicos para distrofia muscular de Duchenne<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>The European Commission has granted Orphan Drug Designation to SGT-003, a promising gene therapy developed by Solid Biosciences, for the treatment of Duchenne muscular dystrophy (DMD). This milestone highlights growing regulatory support for innovative therapies targeting rare diseases with high unmet medical needs. What Is SGT-003? SGT-003 is an investigational gene therapy designed to address [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":7750,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[680,61,195,681,110,170,109],"class_list":["post-7749","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-dmd-orphan-drugs","tag-gene-therapy","tag-orphan-drug","tag-orphan-drug-designation","tag-sgt-003","tag-sgt-003-gene-therapy","tag-solid-biosciences"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/7749","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/comments?post=7749"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/7749\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media\/7750"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media?parent=7749"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/categories?post=7749"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/tags?post=7749"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}